Budesonide gastro-resistant granules - Dr Falk Pharma

Drug Profile

Budesonide gastro-resistant granules - Dr Falk Pharma

Alternative Names: Budenofalk Granules; Budo-San; Intestifalk

Latest Information Update: 29 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dr Falk Pharma
  • Developer Dr Falk Pharma; Merck & Co
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Crohn's disease; Microscopic colitis
  • Phase II Ulcerative colitis

Most Recent Events

  • 16 Jan 2017 Dr Falk Pharma completes a phase III trial in Microscopic colitis in Netherlands, Spain, Lithuania, Czech Republic, Denmark, Belgium, Sweden, Hungary, Germany (EudraCT2008-005994-36)
  • 15 Mar 2016 Biomarkers information updated
  • 10 Jul 2015 Phase-II clinical trials in Ulcerative colitis in Hungary, Latvia (PO) (EudraCT2014-005635-14)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top